2022
DOI: 10.3390/biomedicines10102590
|View full text |Cite
|
Sign up to set email alerts
|

Next-Generation Sequencing Comparative Analysis of DNA Mutations between Blood-Derived Extracellular Vesicles and Matched Cancer Tissue in Patients with Grade 4 Glioblastoma

Abstract: The biological heterogeneity of glioblastoma, IDH-wildtype (GBM, CNS WHO grade 4), the most aggressive type of brain cancer, is a critical hallmark, caused by changes in the genomic mutational asset and influencing clinical progression over time. The understanding and monitoring of the mutational profile is important not only to reveal novel therapeutic targets in this set of patients, but also to ameliorate the clinical stratification of subjects and the prognostic significance. As neurosurgery represents the… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 57 publications
0
1
0
Order By: Relevance
“…In recent times, RNA and proteins carried by EVs through the blood stream have been profiled to find molecular biomarkers positively correlated with many diseases. Indeed, such biomarkers have become useful in keeping track of disease progression and amelioration (11)(12)(13)(14). The latter aspect is even more important in the case of psoriasis where the patient evaluation and follow-up is still based on clinical criteria, mainly the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI).…”
mentioning
confidence: 99%
“…In recent times, RNA and proteins carried by EVs through the blood stream have been profiled to find molecular biomarkers positively correlated with many diseases. Indeed, such biomarkers have become useful in keeping track of disease progression and amelioration (11)(12)(13)(14). The latter aspect is even more important in the case of psoriasis where the patient evaluation and follow-up is still based on clinical criteria, mainly the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI).…”
mentioning
confidence: 99%